Findings

What do systematic reviews say?

1,126 questions · 1,225 findings · 111 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 235 · 19.2%GRADE not reported 260 · 21.2%Very low 207 · 16.9%Low 271 · 22.1%Moderate 177 · 14.4%High 75 · 6.1%

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1542 participants
Very low

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1393 participants
Low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1403 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 4614 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1389 participants
Low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Moderate

Intervention not reported

RVX (high dose, 10 mg to 20 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 1542 participants
Very low

Intervention not reported

RVX (low dose, 2.5 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1399 participants
Low

Intervention not reported

DAB (low dose, 110 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1962 participants
Low

Intervention not reported

DAB (high dose, 150 mg) vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
1 study · 1527 participants
Low

Intervention not reported

APX vs VKA · adults who underwent percutaneous coronary intervention and who have an indication for anticoagulation

1 finding from 1 review

Non‐vitamin K antagonist oral anticoagulants (NOACs) post‐percutaneous coronary intervention: a network meta‐analysis 2019 · Cochrane Headline outcomes only
no estimate extracted
2 studies · 4930 participants
Low

Intervention not reported

Growth and nutritional status:z‐score for height · children and adults with CF

1 finding from 1 review

Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low

Intervention not reported

Mortality · children and adults with CF

The review found no eligible studies for this question.

1 finding from 1 review

Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis 2018 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Intervention not reported

Respiratory outcomes: FEV1 (% predicted): · children and adults with CF

1 finding from 1 review

Vitamin A and beta (β)‐carotene supplementation for cystic fibrosis 2018 · Cochrane Headline outcomes only
no estimate extracted
1 study · 24 participants
Low